Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#1943 Neuroendocrine Tumors Committee of Reference Hospital: Evaluation of Health Care and Research Indicators

Introduction: Neuroendocrine tumors (NETs) require a multidisciplinary approach in expert centers which optimize results improving care and survival.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Jimenez-Fonseca P, Vieitez J, Valdés N, Lauret M, Calvo-Temprano D,

Keywords: committee, indicator, multidisciplinary, resource,

#1937 Clinical Features and Outcomes of Advanced PNETs Treated with Sunitinib: Data from CRIPNET-GETNE Study

Introduction: There are several effective drugs for advanced pancreatic neuroendocrine tumors (PNETs) but the right treatment sequence hasn’t been defined yet.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Solis-Hernandez M

Authors: Solis-Hernandez M, Calvo-Temprano D, Carmona-Bayonas A, García-Carbonero R, Custodio A,

Keywords: Sunitinib, targeted therapies,

#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study

Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Solis-Hernandez M, Carmona-Bayonas A, Calvo-Temprano D, Nuñez B, Custodio A,

Keywords: sunitinib, PNET, choi, recist,

#1423 Multidisciplinary Management and Patient Flow in Neuroendocrine Tumors (NET): Consensus of a Tertiary Hospital

Introduction: Currently, there has been an improvement in diagnostic procedures and treatments of NET. Therefore, an effective teamwork is needed to choose the best approach for patients.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Jimenez-Fonseca P, Avello N, Calvo-Temprano D, Fernández Llana B, García Bernardo C,

Keywords: Mutidisciplinary team, guideline, NET,

#1247 Recist versus Choi Criteria Response Assesment in Patients with Advanced Pancreatic Neuroendocrine Tumor (PNET) Treated with Sunitinib

Introduction: Classically, the response assessment to systemic treatment is based on RECIST. In PNET treated with antiangiogenic targeted therapy as sunitinib there is no good correlation between response rate and progression free survival (PFS). Choi criteria might be an alternative to RECIST to evaluate the effect of sunitinib in patients with advanced PNET

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Solis Hernandez P

Authors: Solis Hernandez M, Calvo-Temprano D, Jiménez-Fonseca P, Faez L, Ruiz A,

Keywords: sunitinib, PNET, Choi, RECIST,